Jasper Therapeutics has finalized its acquisition of Kira Pharmaceuticals in an all-stock deal, creating a new entity focused on immune-mediated diseases. The transaction is supported by a concurrent $132 million private placement co-led by Affinity Asset Advisors and Ikarian Capital. This strategic move combines complementary pipelines and provides substantial funding to advance promising new therapies for patients.
A Strategic Combination for Immunology
The merger positions the combined company to advance a portfolio of biologic agents for various immunologically-driven disorders. This strategic consolidation aims to leverage the scientific expertise and assets of both organizations to create a leader in the immunology space. The new entity will continue trading on Nasdaq under the ticker symbol JSPR, signaling continuity in the public market.
Jeet Mahal, President and CEO of Jasper, expressed excitement about the robust pipeline created by the transaction. Former Kira Chairman Patrick Crutcher highlighted the deal as a transformative step for their product candidates. Both leaders emphasized the goal of developing innovative medicines for patients with significant unmet medical needs.
Bolstered Pipeline and Financial Runway
The combined company's pipeline is led by KP-104, a dual-complement inhibitor for paroxysmal nocturnal hemoglobinuria and renal disorders. Also prominent is briquilimab, an anti-KIT antibody for transplant and immunologic indications, and the preclinical KP-701 for autoantibody-mediated disorders. This diverse portfolio targets several high-value areas within immunology, promising multiple avenues for clinical success.
Key clinical milestones are anticipated across the portfolio over the next few years, funded by the new capital. For KP-104, Phase 2 data in renal indications is expected by late 2026, with plans for a Phase 3 PNH study to be discussed with the FDA. Briquilimab is advancing toward a pre-Biologics License Application meeting, while KP-701 is slated for first-in-human studies in 2027.
The $132 million private placement, combined with a $12 million upfront payment from an out-licensing deal with Mirador Therapeutics, secures the company's financial future. This funding is expected to support operations and key clinical milestones through the second half of 2028. The participation of leading life sciences investors underscores confidence in the combined company's strategy and assets.
Transaction Details and Market Position
The acquisition was structured as a stock-for-stock exchange, with Kira's equity interests swapped for Jasper common and preferred stock. The conversion of the preferred stock is subject to the approval of Jasper's stockholders at an upcoming meeting. This structure facilitates the integration of the two companies while aligning shareholder interests for future growth.
Following the transaction, existing Jasper equityholders will own approximately 6.68% of the combined entity on a fully-diluted basis. Former Kira equityholders will hold about 49.86%, and investors from the private placement will own roughly 43.46%. Additionally, Jasper shareholders will receive a contingent value right tied to potential future monetization of a priority review voucher.
This acquisition and concurrent financing mark a pivotal moment for Jasper Therapeutics, transforming it into a well-capitalized immunology company. With a strengthened pipeline, a clear clinical development path, and a financial runway extending to 2028, the company is well-positioned for growth. The strategic combination is poised to accelerate the development of novel therapies and deliver significant value to both patients and investors.